Neurosense Therapeutics is trading at $2.29, down 13.88%, with no verified company-specific catalyst identified for the October 20 decline. - October 19 news was a U.S. patent application for potential PrimeC use in traumatic brain injury, not an issued patent or treatment approval. - Biotech sector context was positive, with XBI up 2.10%; broader indexes were also higher. No clear same-direction market driver is evident.